Northfield Laboratories, Inc. (NASDAQ: NFLD), a leading developer of oxygen-carrying red blood cell substitute, is focused on addressing the need for the treatment of life-threatening blood loss when oxygen-carrying fluid is required and red blood cells are not available. The company’s PolyHeme product restores lost blood volume and hemoglobin levels and is able to be administered rapidly in massive amounts. For further information, visit the Company’s web site at www.northfieldlabs.com.
- 17 years ago
QualityStocks
Northfield Laboratories, Inc. (NASDAQ: NFLD)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – C3is Inc. (NASDAQ: CISS) Closes Approximately $9 Million Public Offering
C3is (NASDAQ: CISS), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced the closing…
-
Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics
Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…
-
Xeriant Inc. (XERI) Is ‘One to Watch’
Xeriant offers diversified exposure to next-generation aerospace, advanced materials, and sustainability-focused technologies through its strategic…